Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy »

Stanford Health Care

COVID-19 ARDS is characterized by a dysregulated host response that differs from cytokine storm and is modified by dexamethasone. Research square Sarma, A., Christenson, S., Mick, E., Deiss, T., DeVoe, C., Pisco, A., Ghale, R., Jauregui, A., Byrne, A., Moazed, F., Spottiswoode, N., Sinha, P., Zha, B., Neff, N., Tan, M., Serpa, P. H., Ansel, K. M., Wilson, J., Leligdowicz, A., Seigel, E., Sirota, M., DeRisi, J., Matthay, M., Consortium, C., Hendrickson, C., Kangelaris, K., Krummel, M., Woodruff, P., Erle, D., Calfee, C., Langelier, C. 2021

Abstract

We performed comparative lower respiratory tract transcriptional profiling of 52 critically ill patients with the acute respiratory distress syndrome (ARDS) from COVID-19 or from other etiologies, as well as controls without ARDS. In contrast to a cytokine storm, we observed reduced proinflammatory gene expression in COVID-19 ARDS when compared to ARDS due to other causes. COVID-19 ARDS was characterized by a dysregulated host response with increased PTEN signaling and elevated expression of genes with non-canonical roles in inflammation and immunity that were predicted to be modulated by dexamethasone and granulocyte colony stimulating factor. Compared to ARDS due to other types of viral pneumonia, COVID-19 was characterized by impaired interferon-stimulated gene expression (ISG). We found that the relationship between SARS-CoV-2 viral load and expression of ISGs was decoupled in patients with COVID-19 ARDS when compared to patients with mild COVID-19. In summary, assessment of host gene expression in the lower airways of patients with COVID-19 ARDS did not demonstrate cytokine storm but instead revealed a unique and dysregulated host response predicted to be modified by dexamethasone.

View details for DOI 10.21203/rs.3.rs-141578/v1

View details for PubMedID 33469573

View details for PubMedCentralID PMC7814832